drugset / Trial / NCT06539260

Clinical Relationship Between Vitamin D-mediated Th17 and Treg Cells and Parkinson's Disease

NCT06539260

Phase 0 Completed 30 enrolled Suzhou Municipal Hospital of Anhui Province
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to detect the expression levels of vitamin D, Treg, and Th17 in the peripheral blood of patients with Parkinson\'s disease (PD), investigate the impact of Treg/Th17 imbalance on PD patients, and explore the effects of vitamin D intervention on Treg/Th17 imbalance and clinical outcomes. Furthermore, this study aims to delve into the potential mechanisms of vitamin D deficiency and Treg/Th17 imbalance in the pathogenesis of Parkinson\'s disease, ultimately providing new theoretical evidence for the research, prevention, and treatment of PD.

Timeline

Start
2023-01-01
Primary completion
2024-07-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 400 iu